Released May 12, 2026, before the open
10-Q filed May 12, 2026, 42 days after period end · 0001628280-26-034204
Q1 2026 · 10-Q
Revenue—
Net Income-$20.74M-$20.74M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.33-$0.33 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$21,149,000N/M
Operating Cash Flow-$24,128,000N/M
Free Cash Flowderived-$24,128,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$20.74M | -$28.80M | -$14.87M | -$11.31M |
| EPS Diluted | -$0.33 | -$0.48 | -$0.25 | -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR